ISRCTN17231793进行中（未招募）1 期
Phase I trial, HMR code: 22-016 [The full scientific title will be published within 30 months after the end of the trial]
xera Pharma UK Ltd0 个研究点目标入组 104 人开始时间: 2023年6月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 104
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Healthy volunteer
排除标准
- •The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial HMR code: 23-006ISRCTN23220202Gedeon Richter (Hungary)168
进行中（未招募）
1 期
Phase I trial; HMR code: 24-003Healthy volunteersISRCTN16055614Sling Therapeutics, Inc.20
进行中（未招募）
1 期
Phase 1 trial HMR code: 22-017Healthy volunteersISRCTN51803225eurocrine Biosciences (United States)134
进行中（未招募）
1 期
Phase 1 trial HMR code: 23-011Healthy volunteersISRCTN17328380Asceneuron (Switzerland)16
已完成
1 期
Phase I trial, HMR code: 21-014The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN58651193Silence Therapeutics (United Kingdom)32